Clinical Trial Details
| Trial ID: | L4754 |
| Source ID: | NCT00699790 |
| Associated Drug: | Ccr2 Antagonist |
| Title: | Proof of Confidence Study of CCR2 Antagonist (BMS-741672) in Insulin Resistance |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Type 2 Diabetes |
| Interventions: | DRUG: CCR2 Antagonist|DRUG: Placebo |
| Outcome Measures: | Primary: Change in HbA1c, after 12 weeks of treatment | Secondary: Other glycemic, atherosclerosis, lipid and mechanism-based biomarkers will be measured, throughout the 12 weeks of treatment |
| Sponsor/Collaborators: | Sponsor: Bristol-Myers Squibb |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE2 |
| Enrollment: | 58 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT |
| Start Date: | 2009-02 |
| Completion Date: | 2009-12 |
| Results First Posted: | |
| Last Update Posted: | 2015-10-12 |
| Locations: | Local Institution, Dzerzhnsky, 140090, Russian Federation|Local Institution, Moscow, 105229, Russian Federation|Local Institution, Moscow, 117036, Russian Federation|Local Institution, Moscow, 125315, Russian Federation|Local Institution, Nizhny Novgorod, 603126, Russian Federation|Local Institution, Saint Petersburg, 191015, Russian Federation|Local Institution, Saint Petersburg, 195271, Russian Federation|Local Institution, Saint-Petersburg, 190068, Russian Federation|Local Institution, Saint-Petersburg, 194044, Russian Federation|Local Institution, Tyumen, 625023, Russian Federation|Local Institution, Voronezh, 394066, Russian Federation|Local Institution, Yaroslavl, 150023, Russian Federation |
| URL: | https://clinicaltrials.gov/show/NCT00699790 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|